[go: up one dir, main page]

AR116300A1 - Proceso para la preparación de 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]anuleno-2-carboxilato de metilo - Google Patents

Proceso para la preparación de 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]anuleno-2-carboxilato de metilo

Info

Publication number
AR116300A1
AR116300A1 ARP190102550A ARP190102550A AR116300A1 AR 116300 A1 AR116300 A1 AR 116300A1 AR P190102550 A ARP190102550 A AR P190102550A AR P190102550 A ARP190102550 A AR P190102550A AR 116300 A1 AR116300 A1 AR 116300A1
Authority
AR
Argentina
Prior art keywords
fluoropropyl
formula
pyrrolidin
benzo
preparation
Prior art date
Application number
ARP190102550A
Other languages
English (en)
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of AR116300A1 publication Critical patent/AR116300A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12Oxygen or sulfur atoms
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/1616Coordination complexes, e.g. organometallic complexes, immobilised on an inorganic support, e.g. ship-in-a-bottle type catalysts
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02Dicarboxylic acids
    • C07C55/06Oxalic acid
    • C07C55/07Salts thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235Saturated compounds containing more than one carboxyl group
    • C07C59/245Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255Tartaric acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Health & Medical Sciences (AREA)
  • Pyrrole Compounds (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un proceso para preparar 6-(2,4-diclorofenil)-5-[4-[(3S)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7H-benzo[7]anuleno-2-carboxilato de metilo el cual es útil como degradador selectivo del receptor de estrógeno (SERD) e intermediarios para dicho proceso. Reivindicación 1: Un proceso para la preparación del compuesto de fórmula (1) en la forma de base o en una forma de sal, caracterizado porque el compuesto de fórmula (1) se obtiene por un acoplamiento de Suzuki del compuesto de fórmula (2), en donde LG representa un grupo saliente, con un reactivo de organoboro OrganoB-X en donde OrganoB es un derivado de boro y X es un resto (3S)-1-(3-fluoropropil)-3-fenoxipirrolidina de la fórmula (3), seguido opcionalmente de una reacción de salificación. Reivindicación 21: Compuestos de fórmulas (2), (4) y (5), en donde LG representa un grupo saliente.
ARP190102550A 2018-09-07 2019-09-06 Proceso para la preparación de 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]anuleno-2-carboxilato de metilo AR116300A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18306177 2018-09-07

Publications (1)

Publication Number Publication Date
AR116300A1 true AR116300A1 (es) 2021-04-21

Family

ID=63637829

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP190102549A AR116299A1 (es) 2018-09-07 2019-09-06 Sales de 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]anuleno-2-carboxilato de metilo y proceso de preparación de las mismas
ARP190102550A AR116300A1 (es) 2018-09-07 2019-09-06 Proceso para la preparación de 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]anuleno-2-carboxilato de metilo

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP190102549A AR116299A1 (es) 2018-09-07 2019-09-06 Sales de 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]anuleno-2-carboxilato de metilo y proceso de preparación de las mismas

Country Status (19)

Country Link
US (3) US12157721B2 (es)
EP (2) EP3847157B1 (es)
JP (2) JP7413363B2 (es)
KR (2) KR20210057032A (es)
CN (2) CN112638869B (es)
AR (2) AR116299A1 (es)
AU (2) AU2019336532A1 (es)
BR (2) BR112021003061A2 (es)
CA (2) CA3111359A1 (es)
CY (2) CY1125418T1 (es)
DK (2) DK3847157T3 (es)
ES (2) ES2923412T3 (es)
HU (2) HUE059362T2 (es)
IL (2) IL281191B (es)
MX (2) MX2021002666A (es)
SG (2) SG11202102057SA (es)
TW (2) TW202026280A (es)
WO (2) WO2020049150A1 (es)
ZA (2) ZA202101006B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3434272A1 (en) 2017-07-25 2019-01-30 Sanofi Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
CN112638869B (zh) * 2018-09-07 2025-04-25 赛诺菲 6-(2,4-二氯苯基)-5-[4-[(3s)-1-(3-氟丙基)吡咯烷-3-基]氧基苯基]-8,9-二氢-7h-苯并[7]轮烯-2-甲酸甲酯的盐及其制备方法
US12528768B2 (en) 2019-12-09 2026-01-20 Sanofi Crystalline form of a 7H-benzo[7]annulene-2-carboxylic acid derivative
TW202146007A (zh) 2020-02-27 2021-12-16 法商賽諾菲公司 包含阿培利司(alpelisib)與6-(2,4-二氯苯基)-5-[4-[(3s)-1-(3-氟丙基)吡咯啶-3-基]氧苯基]-8,9-二氫-7h-苯并[7]輪烯-2-羧酸之組合
CN115916769B (zh) 2020-06-28 2024-09-10 深圳扬厉医药技术有限公司 并环吲唑类化合物
CN116615414A (zh) * 2020-10-19 2023-08-18 赛诺菲 经取代的6,7-二氢-5h-苯并[7]轮烯化合物及其衍生物、其制备方法及其治疗用途
TW202233572A (zh) 2020-10-19 2022-09-01 法商賽諾菲公司 新穎之經取代的6,7-二氫-5h-苯並[7]輪烯衍生物,其製備方法及其治療用途
WO2022084280A1 (en) 2020-10-19 2022-04-28 Sanofi Substituted 6,7-dihydro-5h-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof
WO2023125700A1 (zh) 2021-12-28 2023-07-06 南京明德新药研发有限公司 四氢环庚吲唑化合物的盐型、晶型
WO2023187086A1 (en) 2022-03-31 2023-10-05 Sanofi Amorphous solid form of amcenestrant
US20250255848A1 (en) * 2022-04-15 2025-08-14 Sanofi Substituted 6,7-dihydro-5h-benzo[7]annulene derivatives, processes for their preparation and therapeutic uses thereof
JP2025512050A (ja) 2022-04-15 2025-04-16 サノフイ 新規の置換された4-アミノ-4-オキソ-ブト-2-エニル誘導体、それらの調製のためのプロセス及びその治療的使用
US20250262186A1 (en) 2022-04-15 2025-08-21 Sanofi Novel substituted fluorinated n-propyl-pyrrolidine and n-propyl-azetidine compounds, processes for their preparation and therapeutic uses thereof
US20250248970A1 (en) 2022-04-15 2025-08-07 Sanofi Novel substituted fluorinated n-propyl-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof
JP2025513063A (ja) 2022-04-15 2025-04-22 サノフイ 新規置換フッ化ビニル-n-プロピル-ピロリジン化合物、それを調製するためのプロセス及びその治療的使用

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06506467A (ja) 1991-03-08 1994-07-21 ローヌ−プーラン ローラー インターナショナル(ホウルディングス) インコーポレイテッド 多環式三級アミンポリ芳香族スクアレンシンセターゼインヒビター
DE19833786A1 (de) 1998-07-18 2000-01-20 Schering Ag Benzocycloheptene, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
ATE286893T1 (de) 2001-01-24 2005-01-15 Chiesi Farma Spa 2h-1-benzopyran-derivative, prozesse zu ihrer herstellung und pharmazeutische zusammensetzungen
EP1417169A2 (en) 2001-08-11 2004-05-12 Bristol-Myers Squibb Pharma Company Selective estrogen receptor modulators
JP4554219B2 (ja) 2002-04-24 2010-09-29 メルク・シャープ・エンド・ドーム・コーポレイション エストロゲン受容体調節剤
EP1577288B1 (en) 2002-12-26 2014-07-23 Eisai R&D Management Co., Ltd. Selective estrogen receptor modulators
MX2007000036A (es) 2004-06-25 2007-05-18 Johnson & Johnson Antagonistas del receptor 2 de citocina quimioatrayente de sales cuaternarias.
JP5354775B2 (ja) 2005-06-14 2013-11-27 ベイラー ユニバーシティ チューブリン結合活性を有するコンブレタスタチンアナログ
CN101679237A (zh) * 2007-05-03 2010-03-24 赛福伦公司 制备(r)-2-甲基吡咯烷和(s)-2-甲基吡咯烷及其酒石酸盐的方法
US8127618B1 (en) 2007-05-18 2012-03-06 Pacesetter, Inc. Implantable micro-electromechanical system sensor
EP2048126A1 (de) 2007-10-11 2009-04-15 Bayer Schering Pharma AG Benzocycloheptanderivate als selektiv wirksame Estrogene
WO2009101634A2 (en) 2008-02-13 2009-08-20 Lupin Limited A novel process for the preparation of eszopiclone
DE102010030538A1 (de) 2010-06-25 2011-12-29 Bayer Schering Pharma Aktiengesellschaft 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
GB2483736B (en) 2010-09-16 2012-08-29 Aragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
US20120130129A1 (en) 2010-11-16 2012-05-24 Baylor University Efficient Method for Preparing Functionalized Benzosuberenes
JP5886873B2 (ja) 2010-12-24 2016-03-16 メルク・シャープ・エンド・ドーム・ベー・フェー N置換アゼチジン誘導体
DE102011087987A1 (de) 2011-12-08 2013-06-13 Bayer Intellectual Property Gmbh 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
JP2015504049A (ja) 2011-12-30 2015-02-05 センタウルス・バイオファーマ・カンパニー・リミテッドCentaurus Biopharma Co.,Ltd. 新規アリールアルケン誘導体およびその選択的エストロゲン受容体調整剤における使用
CN102584687A (zh) 2011-12-30 2012-07-18 北京赛林泰医药技术有限公司 作为选择性雌激素受体调节剂的乙烯衍生物
DK3033086T3 (da) 2013-08-14 2022-01-03 Novartis Ag Kombinationsterapi til behandling af cancer
WO2015028409A1 (de) 2013-08-27 2015-03-05 Bayer Pharma Aktiengesellschaft 6,7-dihydro-5h-benzo[7]annulen-derivate, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
US9675586B2 (en) 2013-12-06 2017-06-13 Genentech, Inc. Estrogen receptor modulator for the treatment of locally advanced or metastatic estrogen receptor positive breast cancer
MX2017004359A (es) 2014-10-03 2017-06-23 Novartis Ag Composiciones farmaceuticas que comprenden alpelisib.
CN112375077A (zh) 2014-12-18 2021-02-19 豪夫迈·罗氏有限公司 四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途
US9845291B2 (en) 2014-12-18 2017-12-19 Genentech, Inc. Estrogen receptor modulators and uses thereof
SG10202104177VA (en) 2015-04-29 2021-05-28 Radius Pharmaceuticals Inc Methods of treating cancer
CN106924210A (zh) 2015-12-29 2017-07-07 北京新领先医药科技发展有限公司 一种含有帕布昔利布的胶囊剂及其制备方法
KR102813742B1 (ko) * 2016-02-15 2025-05-28 사노피 에스트로겐 수용체 조절자로서의 6,7-디하이드로-5h-벤조[7]아눌렌 유도체
ES3039455T3 (en) 2016-11-17 2025-10-21 Sanofi Sa Novel substituted n-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof
EP3434272A1 (en) 2017-07-25 2019-01-30 Sanofi Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
EP3716969A1 (en) 2017-12-01 2020-10-07 Novartis AG Pharmaceutical combination comprising lsz102 and alpelisib
CN109896991B (zh) 2017-12-08 2020-11-20 苏州远智医药科技有限公司 一种δ阿片受体拮抗剂及其用途和药物组合物
CN112638869B (zh) * 2018-09-07 2025-04-25 赛诺菲 6-(2,4-二氯苯基)-5-[4-[(3s)-1-(3-氟丙基)吡咯烷-3-基]氧基苯基]-8,9-二氢-7h-苯并[7]轮烯-2-甲酸甲酯的盐及其制备方法
MX2021005651A (es) 2018-11-16 2021-09-10 Arqule Inc Combinacion farmaceutica para el tratamiento contra el cancer.
WO2020112765A1 (en) 2018-11-30 2020-06-04 Radius Pharmaceuticals, Inc. Elacestrant in combination with abemaciclib in women with breast cancer
MX2021013711A (es) 2019-05-09 2021-12-10 Sanofi Sa Acido 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin -3-il]oxifenil]-8,9-dihidro-7h-benzo[7]anuleno-2-carboxilico para su uso en pacientes con cancer de mama metastasico o avanzado.
AU2020317099A1 (en) * 2019-07-22 2022-02-24 Sun Pharma Advanced Research Company Limited Selective estrogen receptor degrader
WO2021063967A1 (en) 2019-10-01 2021-04-08 Sanofi Novel substituted 6,7-dihydro-5h-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof
CA3159749A1 (en) * 2019-11-04 2021-05-14 Recurium Ip Holdings, Llc Salts and forms of an estrogen receptor modulator
US12528768B2 (en) 2019-12-09 2026-01-20 Sanofi Crystalline form of a 7H-benzo[7]annulene-2-carboxylic acid derivative
TW202146007A (zh) 2020-02-27 2021-12-16 法商賽諾菲公司 包含阿培利司(alpelisib)與6-(2,4-二氯苯基)-5-[4-[(3s)-1-(3-氟丙基)吡咯啶-3-基]氧苯基]-8,9-二氫-7h-苯并[7]輪烯-2-羧酸之組合
KR20220151616A (ko) 2020-03-06 2022-11-15 올레마 파마슈티컬스 인코포레이티드 에스트로겐 수용체-연관 질환의 치료 방법
WO2022084280A1 (en) 2020-10-19 2022-04-28 Sanofi Substituted 6,7-dihydro-5h-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof
TW202233572A (zh) 2020-10-19 2022-09-01 法商賽諾菲公司 新穎之經取代的6,7-二氫-5h-苯並[7]輪烯衍生物,其製備方法及其治療用途
CN116782895A (zh) 2020-11-23 2023-09-19 赛诺菲 包含阿贝西利和6-(2,4-二氯苯基)-5-[4-[(3s)-1-(3-氟丙基)吡咯烷-3-基]氧基苯基]-8,9-二氢-7h-苯并[7]轮烯-2-甲酸的组合
TW202304425A (zh) 2021-04-12 2023-02-01 法商賽諾菲公司 包含瑞博西尼和安森司群(amcenestrant)的組合
TW202304424A (zh) 2021-04-12 2023-02-01 法商賽諾菲公司 包含依維莫司和安森司群的組合

Also Published As

Publication number Publication date
IL281191B (en) 2022-07-01
EP3847156A1 (en) 2021-07-14
HUE059527T2 (hu) 2022-11-28
BR112021003061A2 (pt) 2021-05-11
DK3847157T3 (da) 2022-08-08
ES2924738T3 (es) 2022-10-10
IL281196B2 (en) 2023-02-01
BR112021003440A2 (pt) 2021-05-18
WO2020049153A1 (en) 2020-03-12
CN112638870B (zh) 2025-04-25
MX2021002666A (es) 2021-07-16
TWI803692B (zh) 2023-06-01
ES2923412T3 (es) 2022-09-27
EP3847156B1 (en) 2022-05-04
TW202026280A (zh) 2020-07-16
US12157721B2 (en) 2024-12-03
US20250042849A1 (en) 2025-02-06
IL281196B (en) 2022-10-01
CN112638870A (zh) 2021-04-09
KR20210057031A (ko) 2021-05-20
KR20210057032A (ko) 2021-05-20
DK3847156T3 (da) 2022-07-25
CN112638869B (zh) 2025-04-25
EP3847157B1 (en) 2022-05-18
ZA202101006B (en) 2022-08-31
JP7413363B2 (ja) 2024-01-15
CN112638869A (zh) 2021-04-09
WO2020049150A1 (en) 2020-03-12
IL281191A (en) 2021-04-29
JP2021536471A (ja) 2021-12-27
SG11202102057SA (en) 2021-03-30
US11713296B2 (en) 2023-08-01
CA3111359A1 (en) 2020-03-12
US20210188771A1 (en) 2021-06-24
MX2021002665A (es) 2021-07-16
JP7398436B2 (ja) 2023-12-14
AU2019336532A1 (en) 2021-04-01
AR116299A1 (es) 2021-04-21
US20210188772A1 (en) 2021-06-24
AU2019335542A1 (en) 2021-04-01
IL281196A (en) 2021-04-29
JP2021536468A (ja) 2021-12-27
CY1125418T1 (el) 2024-09-20
EP3847157A1 (en) 2021-07-14
TW202024032A (zh) 2020-07-01
CY1125486T1 (el) 2024-09-20
HUE059362T2 (hu) 2022-11-28
ZA202101079B (en) 2022-09-28
CA3111466A1 (en) 2020-03-12
SG11202102059YA (en) 2021-03-30

Similar Documents

Publication Publication Date Title
AR116300A1 (es) Proceso para la preparación de 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]anuleno-2-carboxilato de metilo
AR114631A1 (es) Métodos e intermedios para preparar compuestos de piridina
AR088449A1 (es) Benzilindazoles sustituidos
AR083399A1 (es) Proceso para la preparacion de cicloheptapiridina como antagonista del receptor de cgrp
PE20070370A1 (es) Compuestos derivados de carboxamidas como agentes fungicidas
AR102570A1 (es) Síntesis de copanlisib, su sal diclorhidrato, intermediarios para su preparación e hidratos de los mismos
CR20160098A (es) Polimorfo de los inhibidores de la syk
AR061924A1 (es) Proceso para elaborar 2- amino -5 - halobenzamidas 3- sustituidas
CR20110432A (es) Pirimidinas fusionadas
PH12015501226A1 (en) Crystalline 6,7-unsaturated-7-carbamoyl morphinane derivative, and method for producing the same
BR112017006253A2 (pt) novos compostos
CY1112283T1 (el) Μεθοδος για την παρασκευη 17-βινυλ-τριφλικων ως ενδιaμεσα
MX2010008375A (es) Derivados de piperidina espirocíclicos substituidos como ligandos de receptores de histamina-3 (h3).
CY1116540T1 (el) Μεθοδος παραγωγης 2'-δεοξυ-5-αζακυτιδινης (δεσιταβινη)
BRPI0821102A2 (pt) Preparação de derivados de di-hidropirrol como intermediários
AR068115A1 (es) Derivado del acido pirazolcarboxilico metodo de produccion del mismo y fungicida
AR095727A1 (es) Preparación de intermediarios de pirimidina
AR065775A1 (es) Procedimiento para preparar 2,6-dicloro-4-(trifluorometil)-fenilhidracina usando mezclas de dicloro-fluoro-trifluorometilbencenos
WO2016089758A3 (en) Organo-1-oxa-4-azonium cyclohexane compounds
AR110119A1 (es) Proceso para la purificación de pirazolpiridazinas
EA200701470A1 (ru) Способы получения производных 4-(фенокси-5-метилпиримидин-4-илокси)пиперидин-1-карбоновой кислоты и родственных соединений
NZ593763A (en) Method of preparing (+)-1,4-dihydro-7-[(3s,4s)-3methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
RU2016138800A (ru) Новый способ получения производных триазина, пиримидина и пиридина
CL2008002777A1 (es) Metodo de preparacion de compuestos diazepinoquinolinicos quirales por recristalizacion en un sistema de solvente ternario.
JP2016539168A5 (es)

Legal Events

Date Code Title Description
FB Suspension of granting procedure